Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - indications as at 9 october 2002: sodium chloride (0.9%) intravenous infusion is indicated for extracellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 4.5 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - indications as at 9 october 2002: hypotonic sodium chloride (0.45%) is mainly used as a hydrating agent solution.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 2.24 g/l; sodium chloride, quantity: 9 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 1.5 g/l; sodium chloride, quantity: 9 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l; sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; calcium chloride dihydrate, quantity: 270 mg/l - injection, solution - excipient ingredients: water for injections - compound sodium lactate solution and 5% glucose is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are compatible with the solutions.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 1025.2 mg - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 512.6 mg - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Israel - engelsk - Ministry of Health

baxter healthcare distribution ltd., israel - glucose as monohydrate - solution for infusion - glucose as monohydrate 500 g / 1 l - glucose - high caloric carbohydrate infusion, hypoglycaemia

Israel - engelsk - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; icodextrin; magnesium chloride hexahydrate; sodium (s) - lactate; sodium chloride - solution for peritoneal dialysis - icodextrin 75 g/l; magnesium chloride hexahydrate 0.051 g/l; calcium chloride dihydrate 0.257 g/l; sodium (s) - lactate 4.5 g/l; sodium chloride 5.4 g/l - dextran - dextran - once daily replacement of a single glucose exchange as part of continuous ambulatory peritoneal dialysis (capd) or automated peritoneal dialysis (apd) in the treatment of chronic renal failure.

Israel - engelsk - Ministry of Health

baxter healthcare distribution ltd., israel - arginine; calcium chloride dihydrate; glycine; histidine; isoleucine; l- alanine; leucine; lysine hydrochloride; magnesium chloride hexahydrate; methionine; phenylalanine; proline; serine; sodium (s) - lactate; sodium chloride; threonine; tryptophan; tyrosine; valine - solution for peritoneal dialysis - tyrosine 0.3 g/l; tryptophan 0.27 g/l; phenylalanine 0.57 g/l; threonine 0.646 g/l; serine 0.51 g/l; proline 0595 g/l; glycine 0.51 g/l; l- alanine 0.951 g/l; valine 1.393 g/l; methionine 0.85 g/l; isoleucine 0.85 g/l; leucine 1.02 g/l; histidine 0.714 g/l; arginine 1.071 g/l; sodium chloride 5.38 g/l; lysine hydrochloride 0.955 g/l; calcium chloride dihydrate 0.184 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium (s) - lactate 4.480 g/l - combinations of electrolytes - combinations of electrolytes - nutritional supplement for malnourished renal failure patients (albumin concentration lower then 35 g/liter) being maintained on peritoneal dialysis.